

## Prevention of Recurrent Kidney Stones: Dietary Versus Pharmacologic Approach

Submission: 01 November 2025 | Acceptance: 20 January 2026 | Publication: 09 April 2026

<sup>1</sup>Dr Muhammad Nasir Ali, <sup>2</sup>Dr Inam Ul Haq, <sup>3</sup>Mansoor Ali, <sup>4</sup>Taimoor Ghori, <sup>5</sup>Khurram Ali, <sup>6</sup>Marwa Riaz

<sup>1</sup>DHQ Hospital Sheikhupura

<sup>2</sup>Urology Department Gulab Devi Teaching Hospital

<sup>3</sup>UHS Lahore

<sup>4</sup>PIMS Islamabad

<sup>5</sup>PIMS Islamabad

<sup>6</sup>UHS Lahore

### Abstract

**Background:** Recurrent nephrolithiasis is a common and costly urologic disorder. There are two basic forms of prevention: dietary modifications and pharmacologic therapy, each applied to specific metabolic states.

**Objective:** Compare dietary interventions to pharmacologic therapy in preventing the recurrence of kidney stone formation.

**Methods:** Two prevention strategies, namely, structured dietary modification and targeted pharmacological therapy, were compared prospectively based on recurrence rates, metabolic changes, and patients' adherence.

**Results:** Both protocols reduced the rate of stone recurrence, and while pharmacologic therapies better corrected abnormalities, dietary interventions were better tolerated and less likely to induce side effects. Tables summarize the recurrence rates and changes in metabolic parameters.


**Conclusion:** Although both dietary and pharmacologic interventions have proved efficacy, specific risk factors of the patient, their metabolic abnormalities, and their adherence habits should govern an individual approach to prevention.

**Keywords:** Kidney Stones, Nephrolithiasis, Recurrence, Dietary Modification, Pharmacological Therapy, Citrate Supplementation, Thiazides, Calcium Oxalate Stones

## Introduction


The paper focuses on major events of the Cold War that give background information concerning terrorism in various countries [1]. The paper tries to justify why various countries introduce tough measures aiming at addressing the act of terrorism yet they fail to eradicate the menace entirely [2]. Recurrent kidney stone disease is an important clinical problem not only for its high prevalence and huge healthcare burden but also for its impact on quality of life. Indeed, a history of one kidney stone conveys a lifetime risk for recurrence of about 50% within 5 to 10 years without any preventive measures [3]. Understanding the

pathophysiology of nephrolithiasis requires consideration of all its influences, including metabolic, dietary, genetic, and environmental ones.



Long-term prevention, tailored to the individual risk profile, will need such knowledge [4]. Modification of diet has remained one of the cornerstones in preventing the recurrence of kidney stones. These usually include increased intake of fluids, reduction of sodium intake, adequate intake of dietary calcium, limitation of animal protein, and limitation of oxalate-rich foods [5]. These dietary measures fix biochemical imbalances which may be present such as hyperoxaluria, hypercalciuria, and low urinary citrate. In fact, several studies show that those patients who adhere to lifestyle-based interventions reduce the recurrence risk significantly [6]. However, strict adherence to such diets is usually hard to do, especially for long-term durations. Generally, pharmacologic therapies are targeted at the specific metabolic aberrations identified in the 24-hour urine studies. Medications most commonly used include potassium citrate for hypocitraturia, thiazide diuretics for hypercalciuria, allopurinol for hyperuricosuria, and alkalinizing agents for uric acid

stones [7]. Such agents have been shown to yield significant improvements in biochemistry and become particularly effective among high-risk stone formers. However, the cost of medication, long-term compliance, and possible side effects must be taken into account [8].



Prevention of recurrent nephrolithiasis is both dietary and pharmacologic, each modality with its advantages. While dietary modalities confer broad benefits with minimal risks, pharmacologic therapies provide precise correction of the underlying metabolic disorders [9]. Hence, the efficacy of both methods will be compared not only in terms of reduction of stone recurrence but also regarding improvements in urinary biochemical parameters and patient compliance [10]. Appreciation of these differences is thus

fundamental to allowing clinicians to tailor prevention strategies that maximize long-term outcomes and minimize recurrence.

### **Methodology**

This was a prospective comparative study in a tertiary urology setup over a period of 24 months. In the present study, 160 adult patients with a history of recurrent calculi that were calcium-based in origin were included. They were divided into two groups: Group A received structured dietary counseling as per established guidelines for the prevention of nephrolithiasis, while Group B patients received pharmacological therapy tailored to metabolic abnormalities identified via 24-hour urine analysis. Followup for recurrence was done every 6 months either by ultrasound or CT. Urinary metabolic parameters were repeated at the beginning, 12, and 24 months. A patient questionnaire along with pill counts was used to assure compliance. Comparison between the two groups was made to assess recurrence and metabolic improvement using appropriate statistical tests.

### **Results**

A total of 160 patients were enrolled in the study, and 152 completed the 24-month follow-up: 78 in Group A and 74 in Group B. The mean ages for the two groups were similar, with no statistical difference shown regarding baseline urinary biochemical abnormalities. Recurrence of stone occurred in 22% of the patients in the dietary group versus 14% in the pharmacologic group. Both groups showed a significant reduction in recurrence compared with historical controls but pharmacologic therapy was more effective, especially in patients with marked metabolic abnormalities such as hypercalciuria or hypocitraturia. In Group B, urinary biochemistry significantly improved. Potassium citrate treatment significantly increased the levels of citrate

in the urine and corrected pH in the urine, particularly in calcium oxalate and uric acid stone formers. The thiazides caused an average 25% fall in urinary excretion of calcium. In the diet intervention, only a modest improvement, mainly a reduction in urinary sodium and low levels of oxalate in the urine, was achieved. However, the biochemical correction was far less than achieved with pharmacotherapy. There was a difference in adherence, as seen between the two groups: dietary adherence was rated as high in 72% of patients in Group A, while consistent medication adherence was seen only in 58% of patients in Group B. Adverse effects included gastrointestinal discomfort, dyspepsia, and mild hypotension in 12% of medicated patients; no serious adverse events occurred in the dietary group. While pharmacological therapy is better for biochemical correction and reduction of recurrence, dietary therapy is better in terms of its tolerability and compliance, playing the central role of being the first-line intervention. The combination of both is useful in selected patients to achieve synergistic effects.

**Table 1. Comparison of Recurrence Rates of Stones**

Parameter	Dietary Group (n=78)	Pharmacological Group (n=74)
<b>Recurrence Rate (%)</b>	22%	14%
<b>Mean Time to Recurrence (months)</b>	13.4	16.8
<b>Adherence (%)</b>	72%	58%

**Table 2. Change in Urinary Metabolic Parameters at 24 Months**

Parameter	Baseline	Dietary Improvement	Pharmacological Improvement
Urinary Calcium (mg/day)	280	-10%	-25%
Urinary Citrate (mg/day)	320	+8%	+32%
Urinary Oxalate (mg/day)	44	-12%	-18%
Urine pH	5.7	+0.2	+0.6

### Discussion

The present study puts into perspective the relative effectiveness of dietary modification versus pharmacologic therapy in the prevention of kidney stone recurrence [11]. Whereas both treatments proved to confer quantifiable benefits and point to the continuance of existing recommendations for individualized prevention based on metabolic evaluation, stone composition, and patient adherence potential, their differences accentuate the need for an individual approach rather than one-size-fits-all management [12]. The fact that there was better biochemical correction in this pharmacological group agrees with several previous studies that drugs such as potassium citrate and thiazide diuretics act directly on the underlying metabolic disturbances [13]. Potassium citrate, by causing a significant increase in the levels of urinary citrate, reduces calcium oxalate super saturation and inhibits crystal formation. On the other hand, thiazides decrease urinary excretion of calcium and are very effective in patients with hypercalciuria. These are the

mechanisms for the greater reduction in recurrence seen in the pharmacological group [14]. Despite such benefits, many barriers to medication compliance remain. A long-term drug therapy places great demands on the patient's motivation and tolerance of the frequently occurring side effects. In our study, 12% of patients developed adverse symptoms; although these were generally mild in nature, findings like these reduce compliance [15]. This has to be remembered when educating and following up on patients about long-term pharmacologic treatments. Though less effective for the correction of severe biochemical abnormalities, diet management options offer more general lifestyle benefits and an exemplary safety profile [16]. A 72% adherence rate would suggest that dietary strategies may be more feasible to sustain over the long term by patients. Generally, only modest improvements in the urinary parameters of calcium and oxalate excretion are required to substantially reduce the risk of stone formation in mildly affected individuals. Furthermore, increased fluid intake and reduced sodium consumption are in general advantageous strategies whatever the subtype of stone [17]. The important conclusion to be derived from the study seems to be that combined therapy may offer the most benefit among patients with multiple metabolic abnormalities or in those with persistence of recurrence. Changes in diet can enhance the action of pharmacological agents and in some instances reduce the dosage of medication [18]. Ultimately, prevention of recurrent nephrolithiasis requires a balance among efficacy, adherence, metabolic findings, and patient preference. Such personalized treatment guided by metabolic urine evaluations should be the cornerstone in the prevention of stones in order to achieve long-term reduction in stone recurrence.

**Conclusion** Both dietary and pharmacological methods are useful in the prevention of recurrent kidney stones [19]. Pharmacological therapy provides superior biochemical correction and greater reduction in recurrence rates while dietary modification provides better adherence and fewer side effects. An

individualized approach—perhaps combining both strategies—yields the most effective long-term outcomes for recurrent stone formers

### Conclusion

Both dietary and pharmacological methods are useful in the prevention of recurrent kidney stones. Pharmacological therapy provides superior biochemical correction and greater reduction in recurrence rates while dietary modification provides better adherence and fewer side effects. What gives the most effective long-term results for recurrent stone formers are individual approaches, probably a combination of both strategies.

### References

1. Allam, A. T., El-Dessouki, A. M., El-Shiekh, R. A., Abou-Hussein, D., Mahmoud, M. A., Marcus, W. H., & Ruby, H. A. (2025). A holistic guide to effective prevention and treatment for kidney stones: a systematic review exploring anti-urolithiasis approaches. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 1-50.
2. Khanam, A., Singh, G., & Narwal, S. (2024). Treatment and prevention of recurrent urolithiasis: insights on molecular mechanism of occurrence and medical care. *Food Chemistry Advances*, 5, 100751.
3. Kulsoom, Ahmad, S., Urwa, Khan, I. A., Awais, Pricope, R., ... & Ali, W. (2025). Associations between clinical, biochemical, and nutritional factors in kidney stone formation and recurrence. *Urolithiasis*, 53(1), 112.

4. Lo, C. Y., Khor, Q. H., Abdullatif, V. A., Delgado, C., Lu, Y., Katz, J., & Sur, R. L. (2025). Systematic review of pharmacological, complementary, and alternative therapies for the prevention of calcium oxalate stones. *Asian Journal of Urology*, 12(2), 169-188.

5. Hsi, R. S., Crivelli, J. J., Yan, P. L., Shahinian, V., & Hollingsworth, J. M. (2024). Comparison of class-specific side effects across preventative pharmacologic therapies for kidney stone disease. *Urology practice*, *11*(1), 172-178.
6. Tunnicliffe, D. J., Wickham, I., Jauré, A., Johnston, B., Mallett, A. J., Mullan, A., ... & Caring for Australian and New Zealanders with Kidney Impairment (CARI) Guidelines Steering Committee. (2025). Identifying and integrating consumer-prioritised topics and outcomes in clinical practice guidelines on managing kidney stones. *BMC nephrology*, *26*(1), 292.
7. Shahzadi, A., Ashfaq, U. A., Khurshid, M., Nisar, M. A., Syed, A., & Bahkali, A. H. (2024). Deciphering multi-target pharmacological mechanism of cucurbita pepo seeds against kidney stones: network pharmacology and molecular docking approach. *Current Pharmaceutical Design*, *30*(4), 295-309.
8. Edyedu, I., Ugwu, O. P. C., Ugwu, C. N., Alum, E. U., Eze, V. H. U., Basajja, M., ... & Aja, P. M. (2025). The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. *Medicine*, *104*(7), e41381.
9. Wang, H., Lu, Z., Yang, W., Li, X., Gao, M., Duan, C., ... & Gao, B. (2025). A study based on reverse network pharmacology of kidney stones identified that quercetin targets the myosin light chain kinase/myosin light chain 2 pathway in human kidney HK-2 cells. *Asian Journal of Urology*.
10. Lin, H., Li, X., Shen, A., & Yin, W. (2025). Pivotal role of AhR protein in the therapeutic efficacy of HuangKui capsule against calcium oxalate-induced kidney damage: An integrated study of

- network pharmacology and experimental verification. *International Journal of Biological Macromolecules*, 145288.
11. Chanchal, D. K., & Sharma, S. K. (2024). Exploring the therapeutic potential of *Madhuca longifolia* in traditional Chinese medicine for the management of kidney stones and various diseases: A review. *Pharmacological Research-Modern Chinese Medicine*, 11, 100452.
  12. Kanbay, M., Copur, S., Bakir, C. N., Hatipoglu, A., Sinha, S., & Haarhaus, M. (2024). Management of de novo nephrolithiasis after kidney transplantation: a comprehensive review from the European Renal Association CKD-MBD working group. *Clinical Kidney Journal*, 17(2), sfae023.
  13. Dai, S., Fang, Q., Li, H. Y., Sun, R., Zhang, H. Y., & Wu, W. (2025). Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of OATF against kidney stones. *Frontiers in Pharmacology*, 16, 1575270.
  14. Qiu, M., Li, S., Zhang, Y., Yan, J., Qin, S., Yin, X., ... & Yang, K. (2025). Multi-dimensional mechanism analysis of *Choerospondias axillaris* (Roxb.) Burt et Hill in treating kidney stones: network pharmacology, molecular docking and in vitro experimental verification. *Frontiers in Pharmacology*, 16, 1501386.
  15. Bao, E., Yang, Y., Jiang, B., Wang, B., Liu, Y., Yang, L., ... & Zhu, P. (2024). An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug

- administration's adverse event reporting system that are associated with the occurrence of kidney stones. *Frontiers in Pharmacology*, 15, 1377679.
16. Liang, H., Xu, Y., Sun, S., Chen, Y., Wang, W., & Hao, Z. (2024). Based on network pharmacology, the mechanism of Dioscin in alleviating renal tubular epithelial cell injury induced by calcium oxalate crystals was explored. *Urolithiasis*, 53(1), 3.
17. Omić, H., Eder, M., Herkner, H., Seitz, C., Kikić, Ž., & Schrag, T. A. (2025). Study protocol for a randomized single-center cross-over study: Dapagliflozin treatment in recurring kidney stone patients. *PLoS One*, 20(4), e0322034.
18. Bhura, N., & Gupta, J. (2025). Exploring phytochemical candidates against nephrolithiasis via similarity searching, network pharmacology, and docking studies. *Biochemical and Biophysical Research Communications*, 151975.
19. Scoglio, M., Bargagli, M., Rintelen, F., Roumet, M., Trelle, S., & Fuster, D. G. (2025). Indapamide or chlorthalidone to reduce urine supersaturation for secondary prevention of kidney stones: protocol for a randomised, double-blind, cross-over trial (INDAPACHLOR). *BMJ open*, 15(6), e101594.
- 20.